Clinical Trial Update: Study of Vadadustat in Hemodialysis Participants With Anemia Switching From Epoetin Alfa [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating vadadustat in hemodialysis patients with anemia switching from epoetin alfa has completed; results posted in 2022.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anemia
• Dialysis-dependent Chronic Kidney Disease

Drugs mentioned

• EPOETIN ALFA (EPOETIN ALFA)
• Vadadustat (vadadustat)

Snippet

Sponsor: Akebia Therapeutics | Conditions: Anemia, Dialysis-dependent Chronic Kidney Disease | Phase 2 | Status: COMPLETED | Results posted: 2022-09-29